IDEXX Laboratories, Inc. $IDXX Stock Position Increased by Rathbones Group PLC

Rathbones Group PLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 1.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 135,499 shares of the company’s stock after buying an additional 1,958 shares during the period. Rathbones Group PLC’s holdings in IDEXX Laboratories were worth $70,756,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of IDXX. J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories in the second quarter valued at $25,000. Elevation Wealth Partners LLC raised its stake in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares during the period. Meeder Asset Management Inc. raised its stake in shares of IDEXX Laboratories by 189.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 55 shares of the company’s stock valued at $29,000 after purchasing an additional 36 shares during the period. Pension & Wealth Management Advisors Inc. purchased a new stake in IDEXX Laboratories during the 3rd quarter worth about $29,000. Finally, Arlington Trust Co LLC lifted its holdings in IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after purchasing an additional 19 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Down 1.9%

IDXX opened at $676.21 on Friday. The firm has a market capitalization of $53.28 billion, a P/E ratio of 45.60 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The company has a fifty day moving average price of $579.87 and a 200-day moving average price of $574.26. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.88.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter last year, the business posted $3.22 earnings per share. The firm’s revenue was up 9.9% compared to the same quarter last year. Equities research analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several analyst reports. Jefferies Financial Group cut their target price on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. The Goldman Sachs Group assumed coverage on IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 price target on the stock. UBS Group increased their price target on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a report on Tuesday, November 3rd. JPMorgan Chase & Co. cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. Finally, Morgan Stanley raised their price objective on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.

Get Our Latest Stock Analysis on IDXX

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 3,979 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $688.64, for a total value of $2,740,098.56. Following the sale, the executive vice president owned 4,076 shares of the company’s stock, valued at $2,806,896.64. This trade represents a 49.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Mazelsky sold 25,140 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $703.19, for a total value of $17,678,196.60. Following the completion of the sale, the insider directly owned 83,803 shares in the company, valued at approximately $58,929,431.57. The trade was a 23.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 41,428 shares of company stock valued at $28,567,934 over the last 90 days. Insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Featured Articles

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.